Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies

Pediatric Hematology and Oncology

Volumn 22, Issue 3, 2005, Pages 247-256

  Hazar, Volkan ^a   Berber, Zafer ^a   Pestereli, Elif ^a   Coskun, Mesut ^a   Yesilipek, Akif ^a   Karpuzoglu, Gulten ^a   Yegin, Olcay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Childhood ALL and NHL; Immunohistochemistry; Soluble Fas; Soluble Fas ligand

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PEDIATRICS; PROGNOSIS; SURVIVAL RATE;

ANTIGENS, CD95; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIGANDS; LYMPHOMA, NON-HODGKIN; LYMPHOPROLIFERATIVE DISORDERS; MALE; MEMBRANE GLYCOPROTEINS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 18044376203     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010590921621     Document Type: Article

References (30)

1. Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444-448.
2. Graubert TA, Ley TJ. How do lymphocytes kill tumor cells? Clin Cancer Res. 1996;2:785-789.
3. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-1349.
4. Bleesing JJ, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood. 2001;98:2466-2473.
5. Bleesing JJ, Straus SE, Fleisher TA. Autoimmune lymphoproliferative syndrome: human disorder of abnormal lymphocyte survival. Pediatr Clin North Am. 2000;47:1291-1310.
6. Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell. 1991;66:233-243.
7. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
8. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995;377:630-622.
9. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol. 1996;133:335-343.
10. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995;270:1189-1192.
11. Runic R, Lockwood CJ, Ma Y, Dipasquale B, Culler S. Expression of Fas ligand by human cytotrophoblasts: implications in placentation and fetal survival. J Clin Endorinol Metab. 1996;81:3119-3122.
12. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759-1762.
13. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
14. Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ruberti G. An N-terminal domain shared by Fas/Apol (CD95) soluble variants prevents cell death in vitro. J Immunol. 1996;156:4622-4630.
15. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood. 1995;85:1562-1569.
16. Miret C, Font J, Molina R, et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res. 2001;21:3053-3059.
17. Hara S, Miyake H, Nakamura I, Arakawa S, Kamidono S, Hara I. Increased Fas ligand expression in the tumor tissue and serum of patients with testicular germ cell tumors with seminomatous elements. Urology. 2001;58:471-476.
18. Mizutani Y, Ilongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer. 2001;92:287-293.
19. Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?. Hepatology. 1999;30:413-421.
20. Kato K, Ohshima K, Ishihara S, et al. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders. Br J Haematol. 1998;103:1164-1166.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
22. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-2135.
23. Patte C, Auperin A, Michon J, et al. Societe Francaise d'Oncologie Pediatrique. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
24. Yufu Y, Choi I, Hirase N, et al. Soluble Fas in the serum of patients with non-Hodgkin's lymphoma: higher concentrations in angioimmunoblastic T-cell lymphoma. Am J Hematol. 1998;58:334-336.
25. Hara T, Tsurumi H, Takemura M, et al. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma. Am J Hematol. 2000;64:257-261.
26. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363-1366.
27. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075-1082.
28. Volm M, Zintl F, Sauerbrey A, Koomagi R. Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia. Anticancer Res. 1999;19:3399-3402.
29. Baryshnikov A, Polosukhina ER, Tupitsin NN, et al. CD95 (FAS/APO1)antigen is a new prognostic marker of blast cells of acute lymphoblastic leukemia patients. Adv Exp Med Biol. 1999;457:251-258.
30. Suminoe A, Matsuzaki A, Hattori H, et al. mRNA expression of apoptosis-associated genes in infant acute lymphoblastic leukemia: low Fas expression is an independent predictor for poor prognosis. Leukemia. 2004;18:365-368.